Related Experiment Video

Updated: May 5, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

13.6K

Is it accurate to separate glucose-6-phosphate dehydrogenase activity in neonatal hyperbilirubinemia as deficient and

Hasan Kilicdag1, Zeynel Gökmen1, Servet Ozkiraz1

  • 1Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Baskent University, Ankara, Turkey.

Pediatrics and Neonatology
|December 12, 2013
PubMed

Insights

Glucose 6-phosphate dehydrogenase (G6PD) activity is crucial for managing severe neonatal hyperbilirubinemia. Lower G6PD levels in infants correlate with longer phototherapy and increased need for exchange transfusions, highlighting the importance of routine G6PD testing.

Area of Science:

  • Neonatal Medicine
  • Biochemistry
  • Pediatric Hematology

Background:

  • Severe neonatal hyperbilirubinemia poses risks for neurological dysfunction.
  • Glucose 6-phosphate dehydrogenase (G6PD) deficiency can impact bilirubin metabolism.
  • Understanding G6PD activity is vital for managing hyperbilirubinemia in newborns.

Purpose of the Study:

  • To investigate glucose 6-phosphate dehydrogenase (G6PD) activity in term and late preterm infants with severe neonatal hyperbilirubinemia.
  • To explore the relationship between G6PD activity levels and the severity and treatment requirements of hyperbilirubinemia.
  • To assess G6PD activity irrespective of deficiency or normal levels.

Main Methods:

  • A cohort of 529 term and late preterm infants (≥35 weeks) with severe hyperbilirubinemia was studied.
  • Serum samples were analyzed for blood group, direct Coombs' test, complete blood count, bilirubin levels, thyroid-stimulating hormone, and G6PD activity.
  • Partial correlation analysis was used to examine the association between G6PD activity and total bilirubin.

Main Results:

  • Significant correlation found between hyperbilirubinemia severity and G6PD activity in both male and female neonates.
  • Male infants with G6PD <12 U/g Hb and female infants with G6PD <16 U/g Hb required longer phototherapy.
  • Decreased G6PD activity was linked to increased phototherapy duration and exchange transfusion necessity.

Conclusions:

  • Routine G6PD level screening in hyperbilirubinemic neonates is essential for effective medical management.
  • Identifying specific G6PD thresholds (males <12 U/g Hb, females <16 U/g Hb) aids in assessing condition severity.
  • Prompt identification and care for severe hyperbilirubinemia in neonates with low G6PD activity are critical to prevent neurological damage.
Abstract

Keywords:
glucose-6-phosphate dehydrogenase activityphototherapysevere neonatal hyperbilirubinemia

More Related Videos

Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue06:18

Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue

Published on: June 21, 2018

11.3K
Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism07:59

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism

Published on: August 19, 2021

4.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
35
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K